Mesenchymal-Stem-Cell-Derived Extracellular Vesicles Mitigate Trained Immunity in the Brain

Area of Science:

• Neuroimmunology
• Regenerative Medicine
• Innate Immunity

Background:

• Trained immunity, an innate immune cell memory, can exacerbate neuropathologies.
• Mesenchymal stem cells (MSCs) show brain repair potential but have safety concerns.
• MSC-derived extracellular vesicles (EVs) offer a safer alternative therapy.

Purpose of the Study:

• To investigate the therapeutic potential of MSC-derived EVs in mitigating trained immunity-induced neuropathology.
• To evaluate MSC-EVs' efficacy in reducing brain inflammation and amyloid-beta burden.
• To explore the molecular mechanisms underlying MSC-EVs' therapeutic effects.

Main Methods:

• Activation of trained immunity in the brain using lipopolysaccharides.
• Administration of MSC-derived EVs to mice models.
• Assessment of inflammatory responses and amyloid-beta levels.
• Investigation of the role of IL-10 in MSC-EV therapy.

Main Results:

• MSC-derived EVs demonstrated comparable efficacy to MSCs in mitigating trained immunity.
• MSC-EV administration reduced acute inflammatory responses in stroke models.
• MSC-EVs alleviated increased amyloid-beta load in APP/PS1 mice.
• IL-10 was identified as crucial for the therapeutic effects of MSC-EVs.

Conclusions:

• MSC-derived EVs show significant therapeutic potential for mitigating trained immunity in the brain.
• EV-based regenerative strategies may offer a viable treatment for neuropathologies associated with trained immunity.
• This study highlights the promise of extracellular vesicles in neuroinflammation and neurodegenerative disease treatment.